deltatrials
Completed PHASE2 INTERVENTIONAL 2-arm NCT02983617

Safety and Efficacy of the Combination of Tirabrutinib and Entospletinib With and Without Obinutuzumab in Adults With Chronic Lymphocytic Leukemia (CLL)

A Prospective, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib (GS-4059) and Entospletinib With and Without Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia

Sponsor: German CLL Study Group

Conditions Chronic Lymphocytic Leukemia
Interventions Entospletinib Obinutuzumab Tirabrutinib
Updated 26 times since 2017 Last updated: Dec 17, 2021 Started: Apr 6, 2017 Primary completion: Feb 20, 2019 Completion: Oct 1, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Chronic Lymphocytic Leukemia and is currently completed. German CLL Study Group leads this study, which shows 26 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Apr 2017 · 59 days · monthly snapshot~Apr 2017 – ~May 2017 · 30 days · monthly snapshot~May 2017 – ~Aug 2017 · 3 months · monthly snapshot~Aug 2017 – ~Sep 2017 · 31 days · monthly snapshot~Sep 2017 – ~Oct 2017 · 30 days · monthly snapshot~Oct 2017 – ~Dec 2017 · 2 months · monthly snapshot~Dec 2017 – ~Feb 2018 · 2 months · monthly snapshot~Feb 2018 – ~Mar 2018 · 28 days · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Apr 2019 · 6 months · monthly snapshot~Apr 2019 – ~Oct 2019 · 6 months · monthly snapshot~Oct 2019 – ~Mar 2020 · 5 months · monthly snapshot~Mar 2020 – ~Oct 2020 · 7 months · monthly snapshot~Oct 2020 – ~Dec 2020 · 2 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshot~Dec 2021 – ~Jan 2022 · 31 days · monthly snapshot~Jan 2022 – ~Jul 2024 · 30 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 11 months · monthly snapshot

Change History

26 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jan 2022 — Jul 2024 [monthly]

    Completed PHASE2

  5. Dec 2021 — Jan 2022 [monthly]

    Completed PHASE2

▶ Show 21 earlier versions

  1. Jan 2021 — Dec 2021 [monthly]

    Completed PHASE2

  2. Dec 2020 — Jan 2021 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  3. Oct 2020 — Dec 2020 [monthly]

    Active Not Recruiting PHASE2

  4. Mar 2020 — Oct 2020 [monthly]

    Active Not Recruiting PHASE2

  5. Oct 2019 — Mar 2020 [monthly]

    Active Not Recruiting PHASE2

  6. Apr 2019 — Oct 2019 [monthly]

    Active Not Recruiting PHASE2

  7. Oct 2018 — Apr 2019 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  8. Sep 2018 — Oct 2018 [monthly]

    Recruiting PHASE2

  9. Aug 2018 — Sep 2018 [monthly]

    Recruiting PHASE2

  10. Jul 2018 — Aug 2018 [monthly]

    Recruiting PHASE2

  11. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE2

  12. Mar 2018 — Jun 2018 [monthly]

    Recruiting PHASE2

  13. Feb 2018 — Mar 2018 [monthly]

    Recruiting PHASE2

  14. Dec 2017 — Feb 2018 [monthly]

    Recruiting PHASE2

  15. Oct 2017 — Dec 2017 [monthly]

    Recruiting PHASE2

  16. Sep 2017 — Oct 2017 [monthly]

    Recruiting PHASE2

  17. Aug 2017 — Sep 2017 [monthly]

    Recruiting PHASE2

  18. May 2017 — Aug 2017 [monthly]

    Recruiting PHASE2

  19. Apr 2017 — May 2017 [monthly]

    Recruiting PHASE2

  20. Feb 2017 — Apr 2017 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  21. Jan 2017 — Feb 2017 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • German CLL Study Group
  • Gilead Sciences
Data source: Gilead Sciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aschaffenburg, Germany , Bremen, Germany , Cologne, Germany , Dortmund, Germany , Freiburg im Breisgau, Germany , Hamburg, Germany , Heidelberg, Germany , Herne, Germany , Kiel, Germany , Manheim, Germany and 5 more locations